Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in CLL

moasc

2 years
122 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Miguel Risco, MD, from UC-Irvine Department of Hematology and Oncology joins us at MOASCs Spotlight On® Hematology in Huntington Beach to present "Initial Results of the Phase 2 Treatment Naive Cohort in a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Chronic lymphocytic leukemia."
Up Next Autoplay